131 related articles for article (PubMed ID: 9671879)
1. Early prostate cancer detection and potential for surgical cure in men with poorly differentiated tumors.
Perrotti M; Rabbani F; Russo P; Solomon MC; Fair WR
Urology; 1998 Jul; 52(1):106-10. PubMed ID: 9671879
[TBL] [Abstract][Full Text] [Related]
2. Role of radical prostatectomy in patients with prostate cancer of high Gleason score.
Tefilli MV; Gheiler EL; Tiguert R; Banerjee M; Sakr W; Grignon D; Wood DP; Pontes JE
Prostate; 1999 Apr; 39(1):60-6. PubMed ID: 10221268
[TBL] [Abstract][Full Text] [Related]
3. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
4. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
Ohori M; Goad JR; Wheeler TM; Eastham JA; Thompson TC; Scardino PT
J Urol; 1994 Nov; 152(5 Pt 2):1843-9. PubMed ID: 7523732
[TBL] [Abstract][Full Text] [Related]
5. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
Qi P; Tsivian M; Abern MR; Bañez LL; Tang P; Moul JW; Polascik TJ
Urol Oncol; 2013 Nov; 31(8):1527-32. PubMed ID: 22795501
[TBL] [Abstract][Full Text] [Related]
6. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
[TBL] [Abstract][Full Text] [Related]
7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
8. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
9. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b.
Freedland SJ; Partin AW; Epstein JI; Walsh PC
Cancer; 2004 Apr; 100(8):1646-9. PubMed ID: 15073852
[TBL] [Abstract][Full Text] [Related]
10. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
11. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL; Blute ML; Lerner SE; Bergstralh EJ; Bostwick DG; Zincke H
Mayo Clin Proc; 1998 May; 73(5):401-6. PubMed ID: 9581578
[TBL] [Abstract][Full Text] [Related]
12. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
[TBL] [Abstract][Full Text] [Related]
13. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
15. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
17. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
Cookson MS; Fleshner NE; Soloway SM; Fair WR
Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
[TBL] [Abstract][Full Text] [Related]
19. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy.
Tombal B; Querton M; de Nayer P; Sauvage P; Cosyns JP; Feyaerts A; Opsomer R; Wese FX; Van Cangh PJ
Urology; 2002 Feb; 59(2):256-60. PubMed ID: 11834398
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
